

REMARKS

Claims 77-80 and 89-136 are pending in the application. Claims 1-76, 81-88, and 137-140 have been canceled. Claims 77-80 have been amended to clarify the nature of the claimed mice and to address the claim objections. Exemplary support for the amendments is located on pages 32 and 35 of the specification. Claims 93-100 are amended to correct the antecedent basis. No new matter is introduced.

Applicants acknowledge with appreciation the time and courtesy extended by the Examiner toward Applicants' undersigned representative during a telephone interview conducted on July 27, 2007. In particular, the outstanding enablement rejection was discussed. Applicants would like to note that the Examiner indicated that the enablement rejection would be overcome by the amendments submitted herein. Further discussion focused on advancement of prosecution of the application. The Examiner's comments in this regard are appreciated.

Objections to claims 77-80 have been made in recitation of a comma after the term "gene-targeted" and in recitation of the phrases "said rodent" and "said mammal." Applicants have amended the claims to clarify that the presenilin-1 mutation is a gene-targeted mutation and to recite a murine amyloid precursor protein. Withdrawal of the objections is respectfully requested.

Claims 77-80 and 89-136 are rejected under 35 U.S.C. § 112, first paragraph for alleged lack of enablement. Applicants have amended claims 77-80 to clarify the nature of the claimed mice as supported by the present specification. The amended claims encompass mice heterozygous or homozygous for a human mutation of the presenilin-1 gene, wherein the mutation is P264L and the mutation is a gene-targeted mutation, and heterozygous or homozygous for a murine amyloid precursor protein gene, wherein the murine amyloid precursor protein gene comprises at least one human FAD Swedish mutation and a humanized A β nucleotide sequence. One skilled in the art would have been able to make and use the claimed mice in view of the high skill in the art of transgenics at the time of the invention, the guidance provided by the specification and the working examples set forth therein, and the knowledge in the art. The specification teaches methods of making mice gene-targeted for a presenilin-1 P264L mutation and crossing such mice with either gene-

DOCKET NO.: CEPH-2456
Application No.: 10/797,289
Office Action Dated: April 30, 2007

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

targeted or transgenic mice having the claimed amyloid precursor protein gene to arrive at the present invention. The claimed mice are exemplified in the specification on page 32 and in Example 8. Because it would not have required undue experimentation by one skilled in the art at the time of the invention to make and use the present invention in view of the guidance provided by the present specification and the working examples set forth therein, withdrawal of the enablement rejection is respectfully requested.

CONCLUSION

Applicants believe all claims now pending in this application are in condition for allowance. The issuance of a Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a further telephone conference would expedite prosecution of this application, the undersigned may be contacted at 215.564.8978.

Respectfully submitted,

Date: July 27, 2007

/Felicity E. Groth/
Felicity E. Groth
Registration No. 47,042

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439